Coronavirus disease-2019 (COVID-19) is a novel infectious disease, mainly affecting the respiratory tract, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV2). COVID-19 emerged in Wuhan, China, in December […] Read more
IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens Following Neoadjuvant Therapies
Sanja Dacic+more
Treatment guidelines recommend neoadjuvant or adjuvant therapies with surgery for patients with large primary tumors or clinical evidence of intrathoracic nodal spread.1,2 A recent joint IASLC–U.S. Food and Drug Administration […] Read more
The RAMES Study: A New Strategy of Targeting Angiogenesis in Mesothelioma
Federica Grosso, MD+more
At this year’s American Society of Clinical Oncology Virtual Meeting, the final results of the RAMES study were presented.1 RAMES was a prospective, placebo-controlled, phase II, randomized study in which […] Read more
Elimination of Clinical Trial Disparities Requires a New Lens for Viewing Justice, New Approach to Patient’s Role
By Joy Curzio Although there has been tremendous progress in lung cancer over the past 10 years, with a number of new drug indications being approved in the United States […] Read more
Immunotherapy, TKIs for Resectable/Resected NSCLC: Dr. Masahiro Tsuboi Provides a Comprehensive Overview of Promising Phase II Data, Phase III Status
By Jill Daigneault, PhD Surgical outcomes for early-stage NSCLC are still very poor due to the high rate of recurrence through distant metastases. It is likely that these distant metastases […] Read more
First-line Sintilimab Plus Platinum-Based Chemotherapy Prolongs PFS in Advanced Nonsquamous NSCLC
By Kara Nyberg, PhD Adding sintilimab, an anti-PD-1 antibody, to first-line platinum-based chemotherapy enhances efficacy in patients with locally advanced or metastatic nonsquamous NSCLC. In the randomized, placebo-controlled, phase III […] Read more
Deeper Dive: A Plethora of Prediction Models
Annette McWilliamsBy Annette McWilliams, MBBS, FRACP, MD, FRCPSC In reference to: Nemesure B, Clouston S, Albano D, Kuperberg S, Bilfinger TV. Will that pulmonary nodule become cancerous? A risk prediction model […] Read more
Re-establishing protocols and systems for accurate and timely diagnosis and staging despite fears and high volume is critical to patient survival. Read more
Can We Use the Word ‘Cure’ for a Subset of Selected Patients With Advanced NSCLC?
Karen L. ReckampBy Karen L. Reckamp, MD When advanced NSCLC is diagnosed, the word “cure” is avoided; we focus on palliation of symptoms with prolonged survival. Unfortunately, there are more than 200,000 […] Read more
Small Steps Forward in SCLC: Is a Giant Leap on the Horizon?
Carl M. GayThe absence of an OS benefit in more than 3 decades of clinical trials for extensive-stage SCLC (ES-SCLC) had become an all-too-familiar refrain among the introductions to numerous publications and […] Read more